NCI-2022-04696

A Phase 1, First-In-Human, Dose Escalation and Expansion, Multicenter Study of XMT1660 in Participants with Solid Tumors

This is an early research study testing a new experimental cancer drug named XMT1660 for the first time in humans. The study is for people with advanced or hard-to-treat solid tumors, such as certain breast, ovarian, or endometrial cancers, where other treatments have stopped working. XMT1660 is a type of targeted cancer drug called an antibody–drug conjugate (ADC). It works by finding cancer cells that have a specific marker called B7-H4 on their surface and delivering a small dose of powerful chemotherapy directly into those cancer cells — which may help kill the cancer while causing fewer side effects to healthy cells.

Advanced: Advanced breast cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

antibody–drug conjugate (ADC): ADCs have two parts: an antibody that targets cancer cells and a chemotherapy drug that kills cancer cells.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05377996

Clinical Trial Site: Sinai

To see all available clinical trials click here.